Correlation Study of Lipid Metabolites as Markers of Hepatocellular Carcinoma
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: diagnosed by traditional diagnostic markers（such as AFP or CT etc.）.
- Who it may be relevant to
- Registry conditions: Hepatocellular Carcinoma. Basic parameters: 18 years — 80 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
As one of the common malignant tumors in China, primary liver cancer, whose incidence rate and mortality rate are always in the top five, is seriously threatening the health of people. Therefore, early diagnosis and treatment of primary liver cancer are of great significance. In recent years, the incidence of primary liver cancer, which is caused by hepatic steatosis or metabolic dysfunction-related liver disease, is increasing year by year, and it has become one of the fastest rising causes in some developed countries. More and more studies have also confirmed that the levels of different kinds of lipids and their metabolites are correlated with the development of hepatocellular carcinoma. In this study, the researchers performed qualitative and quantitative analyses of various common lipid metabolites in plasma and liver cancer tissues of hepatic resection patients with hepatocellular carcinoma, collected tumor-related pathological data from the patients, and investigated the correlation between the lipid metabolites and the development of hepatocellular carcinoma, in order to provide a new idea for the early diagnosis and treatment of primary hepatocellular carcinoma, as well as for screening of hepatocellular carcinoma markers.
Interventions
- Diagnostic test diagnosed by traditional diagnostic markers（such as AFP or CT etc.）
A prospective observational cohort study to explore the advantages of lipid metabolites as diagnostic markers for hepatocellular carcinoma compared to traditional diagnostic markers for hepatocellular carcinoma (e.g., AFP, enhanced CT, etc.).
Primary outcome measures
- Lipid Metabolite Levels [Time frame: Pre-operative and 1, 3 and 5 days post-operatively]
Eligibility criteria
Inclusion criteria
- Patients aged 18-80 years old undergoing hepatic resection for hepatocellular carcinoma (diagnostic criteria for hepatocellular carcinoma refer to the guidelines for the diagnosis and treatment of primary hepatocellular carcinoma).
- Voluntary signing of informed consent
Exclusion criteria
- In the judgment of the investigator, they are not suitable to participate in this study.
- Patients with hepatic malignant tumors with invasion of the main portal vein and its first-order branches, the common hepatic duct and its first-order branches, the main hepatic vein and the inferior vena cava, or extrahepatic metastases.
- Surgery with biliary tract exploration or reconstruction in the presence of biliary obstruction.
- Surgery combined with splenectomy or splenic artery ligation
- Preoperative combination of cardiac, pulmonary, renal and other organs with major underlying diseases.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Study design
- Observational model
- Cohort
Study locations
China · 1 center
- Nanfang Hospital — Guangzhou
Publications
- Lei Y, Xie C, Mo X, Zhuang B, Li Q, Liu C, Liao L, Wang B, Zeng M, Tang S, Liu H, Xiao Y, Li S, Cai D, Li C, Zhou J, Li J, Li Y, Wang K. Preoperative plasma ceramide profiling coupled with machine learning accurately predicts recurrence of hepatocellular carcinoma after resection. Lipids Health Dis. 2025 Nov 6;24(1):355. doi: 10.1186/s12944-025-02749-6. PMID 41194075
Identifiers
NCT: NCT06623474 · NFEC-2024-361